Do Growth Hormone Peptides Cause Cancer? | The Truth About IGF-1
Do growth hormone secretagogues increase cancer risk?This episode breaks down the real science behind IGF-1, cancer biology, and compounds like MK-677, Ipamorelin, Sermorelin, CJC-1295, and Tesamoreli...
25 Touko 15min
BPC-157 and Cancer: What the Studies Actually Show
Does BPC-157 cause cancer — or is that claim being oversimplified?In this episode of Peptides Explained, we take a study-review approach to one of the biggest concerns surrounding BPC-157: its potenti...
18 Touko 30min
Tesamorelin Explained: Visceral Fat, Growth Hormone & Real-World Outcomes
Tesamorelin is one of the few peptides with FDA approval—but its effects on visceral fat and growth hormone signaling have made it a major topic in metabolic health and body composition circles.In thi...
11 Touko 8min
Retatrutide Explained: The Triple Agonist Changing Obesity Medicine
Retatrutide may represent the next evolution in metabolic medicine.In this deep-dive episode of Peptides Explained, we break down the science behind the investigational “triple agonist” peptide that’s...
6 Touko 12min
Minimal Effective Dose: The Key to Preventing Muscle Loss on GLP-1s
Using the minimal effective dose of GLP-1 medications may be the key to preserving muscle during weight loss. This episode explains how to implement it alongside nutrition and training.
28 Huhti 15min
GLP-1 Drugs... Are They Destroying Muscle? — What Semaglutide, Tirzepatide & Retatrutide Data Actually Shows
A clinical deep dive into the muscle loss problem on GLP-1 medications. Semaglutide, tirzepatide, and the investigational triple agonist retatrutide all produce remarkable weight loss — but clinical t...
22 Huhti 21min
The Peptide Ban Is Ending: FDA Officially Begins Reclassification Process for BPC-157, TB-500 & More
Breaking news episode. On April 15, 2026, the FDA formally initiated the reclassification process for BPC-157, TB-500, and other peptides restricted since 2023 — publishing a Federal Register notice a...
16 Huhti 24min
